What is the appropriate dosing regimen of Fixcom (rifampicin 120 mg, isoniazid 50 mg, pyrazinamide 300 mg, ethambutol 75 mg) for an adult weighing 45–54 kg, and how should it be administered and monitored?

Dosing Regimen for Fixcom in Adults Weighing 45–54 kg

For an adult weighing 45–54 kg with drug-susceptible tuberculosis, administer 5 tablets of Fixcom (rifampicin 120 mg, isoniazid 50 mg, pyrazinamide 300 mg, ethambutol 75 mg) once daily for the initial 2-month intensive phase, followed by a 4-month continuation phase with rifampicin and isoniazid only. 1

Dosing Breakdown

The 45–54 kg weight band requires 5 tablets daily of the fixed-dose combination, which provides:

• Rifampicin: 600 mg (10 mg/kg for a 50 kg patient)
• Isoniazid: 250 mg (5 mg/kg for a 50 kg patient)
• Pyrazinamide: 1500 mg (30 mg/kg for a 50 kg patient)
• Ethambutol: 375 mg (7.5 mg/kg for a 50 kg patient)

This dosing aligns with the FDA-approved Rifater® formulation specifications, which explicitly states that patients weighing 45–54 kg should receive 5 tablets daily 1. The British Thoracic Society guidelines confirm that this fixed-dose combination (containing rifampicin 120 mg, isoniazid 50 mg, and pyrazinamide 300 mg per tablet) has proven bioavailability and clinical efficacy 2.

Treatment Phases

Initial Phase (2 months)

• Duration: 56 doses over 8 weeks (daily administration) or 40 doses over 8 weeks (5 days/week with directly observed therapy)
• Drugs: All four drugs (rifampicin, isoniazid, pyrazinamide, ethambutol)
• Regimen rating: Grade A (preferred), based on randomized clinical trials 3

Continuation Phase (4 months)

• Duration: 126 doses over 18 weeks (daily) or 90 doses over 18 weeks (5 days/week)
• Drugs: Rifampicin and isoniazid only
• Total treatment: 26 weeks (6 months) for uncomplicated pulmonary TB 3

Critical exception: Extend the continuation phase to 7 months (31 weeks total treatment) if the patient has cavitary disease on chest radiograph AND positive sputum cultures at 2 months 3.

Administration Guidelines

• Timing: Administer once daily, either 1 hour before or 2 hours after meals with a full glass of water 4
• Directly Observed Therapy (DOT): Strongly recommended for all patients to ensure adherence and prevent drug resistance 3
• Pyridoxine supplementation: Add 25–50 mg daily to prevent isoniazid-induced peripheral neuropathy 5, 6

Monitoring Requirements

Baseline Assessment

• Baseline liver function tests (AST/ALT, bilirubin)
• HIV testing
• Hepatitis B and C serology
• Visual acuity testing (Snellen chart) and color discrimination (Ishihara test) for ethambutol 1
• Baseline weight and body mass index

During Treatment

Clinical monitoring (monthly):

• Symptom assessment for hepatotoxicity (fever, malaise, vomiting, jaundice)
• Visual disturbances (blurred vision, scotomata, color discrimination changes)
• Adherence assessment
• Weight monitoring

Laboratory monitoring:

• If baseline liver function is normal: Repeat only if symptoms develop 2
• If baseline AST/ALT is 1–2× normal: Repeat at 2 weeks, then as needed based on trend 2
• If baseline AST/ALT is ≥2× normal: Monitor weekly for 2 weeks, then every 2 weeks until normalized 2

Stop all hepatotoxic drugs immediately if:

• AST/ALT rises to ≥5× upper limit of normal, OR
• Bilirubin becomes elevated 2

Ethambutol-specific monitoring:

• Monthly visual acuity and color discrimination testing, especially if dose exceeds 15 mg/kg or treatment extends beyond 2 months 1
• Discontinue permanently if any visual toxicity develops 1

Bacteriologic Monitoring

• Sputum smear and culture at completion of 2 months (end of intensive phase)
• If culture remains positive at 2 months with cavitary disease: extend continuation phase to 7 months 3
• Sputum culture at treatment completion
• Follow-up cultures if symptoms recur

Important Caveats

Weight-band dosing limitations: Recent pharmacokinetic studies demonstrate that patients in lower weight bands (including 45–54 kg) achieve lower rifampicin exposures compared to higher weight bands 7, 8. However, the current guideline-recommended dosing remains the standard of care until revised formulations become available.

HIV co-infection considerations:

• If CD4 count <100 cells/μL, avoid once-weekly rifapentine regimens 3
• Monitor for drug-drug interactions with antiretroviral therapy, particularly efavirenz (which increases isoniazid clearance by 24%) 7
• May require extended treatment duration based on clinical and bacteriologic response 6, 9

Drug resistance concerns: The four-drug initial regimen is essential unless community isoniazid resistance is <4% AND the patient has no prior TB treatment, no exposure to drug-resistant cases, and is not from a high-prevalence area 3, 9. If isoniazid resistance is confirmed, continue rifampicin and ethambutol for minimum 12 months 9.

Formulation quality: Ensure use of WHO-prequalified fixed-dose combinations, as bioavailability varies significantly between manufacturers 10. The urine should turn orange/pink, providing a simple compliance check 2.